- Home
- BCHT vs MREO Comparison
BCHT vs MREO Comparison
Compare BCHT & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCHT | MREO |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United Kingdom |
| Employees | 20 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.2M | 53.4M |
| IPO Year | 2026 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BCHT | MREO |
|---|---|---|
| Price | $1.91 | $0.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $15.00 | $1.50 |
| AVG Volume (30 Days) | 154.3K | ★ 1.7M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | $13.42 | $5,184.20 |
| Revenue Next Year | $61.22 | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $0.20 |
| 52 Week High | $2.48 | $2.37 |
Technical Indicators
Market Signals| Indicator | BCHT | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 50.35 | 57.32 |
| Support Level | $1.46 | $0.29 |
| Resistance Level | $2.28 | $0.36 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 16.94 | 88.36 |
Price Performance
Historical ComparisonAbout BCHT Birchtech Corp. Common Stock
Birchtech Corp is a provider of specialty activated carbon technologies, delivering solutions for air and water purification. It provides patented and proprietary Sorbent Enhancement Additive (SEA) technologies for mercury emissions capture to the coal-fired utility sector, and is developing water purification technologies with a specialization on forever chemicals such as PFAS and PFOS. Geographically, the company derives all of its revenue from the United States.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).